I. PURPOSE

To define and describe the accepted indications for Jemperli™ (dostarlimab-gxly) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR

2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies AND

4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND

5. When applicable, generic alternatives are preferred over brand-name drugs.

**B. Endometrial Carcinoma**

1. **NOTE:** The preferred immunotherapy-per NCH Policy- for dMMR/MSI-High, recurrent, or advanced/metastatic endometrial carcinoma, that has progressed on prior platinum chemotherapy is Keytruda (pembrolizumab). This recommendation is based on a lack of level 1 evidence (randomized trial and/or meta-analysis) showing superior efficacy of Jemperli (dostarlimab-gxly) over Keytruda (pembrolizumab). Please see UM ONC_1263 Keytruda (pembrolizumab) policy.

2. Jemperli (dostarlimab-gxly) may be used as a single agent as subsequent line systemic therapy for unresectable or metastatic dMMR (deficient Mis-Match Repair)/MSI-High(MicroSatellite Instability-High) endometrial carcinoma that has progressed following prior treatment with a platinum containing regimen AND the tumor is confirmed to be dMMR/MSI-High by any standard test.

**III. EXCLUSION CRITERIA**

A. Disease progression while taking Jemperli (dostarlimab-gxly) or on prior immunotherapy (anti-PD-L1 or PD-1 inhibitor).

B. Concurrent use with other anti-cancer therapies (e.g., chemotherapy, endocrine therapy, targeted therapy, radiotherapy, or immunotherapy).

C. Dosing exceeds single dose limit of Jemperli (dostarlimab-gxly) 500 mg every 3 weeks or 1,000 mg every 6 weeks.

D. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

**IV. MEDICATION MANAGEMENT**

A. Please refer to the FDA label/package insert for details regarding these topics.

**V. APPROVAL AUTHORITY**

A. Review – Utilization Management Department

B. Final Approval – Utilization Management Committee

**VI. ATTACHMENTS**

A. None

**VII. REFERENCES**


